Premium
Intestinal microbial conversion of cholesterol to coprostanol in man
Author(s) -
Midtvedt T.,
Lingaas E.,
CarlstedtDuke B.,
HÖVerstad T.,
Midtvedt A. C.,
Saxerholt H.,
Steinbakk M.,
Norin K. E.
Publication year - 1990
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/j.1699-0463.1990.tb05004.x
Subject(s) - coprostanol , bacitracin , antibiotics , ampicillin , nalidixic acid , erythromycin , ofloxacin , clindamycin , microbiology and biotechnology , cholesterol , tinidazole , vancomycin , medicine , metronidazole , pharmacology , biology , ciprofloxacin , bacteria , sterol , genetics , staphylococcus aureus
The intestinal microbial conversion of cholesterol to coprostanol has been measured in groups of healthy subjects before, during and after they received the antibiotics ampicillin, bacitracin, clindamycin, co‐trimoxazole, doxycycline, erythromycin, metronidazole, nalidixic acid, ofloxacin or vancomycin orally for 6 days. Before they received antibiotics, the subjects demonstrated two distinct patterns of cholesterol conversion. One pattern was characterised by extensive conversion of cholesterol, the other by little or no conversion. Intake of bacitracin, clindamycin, erythromycin, metronidazole and vancomycin significantly reduced the conversion to coprostanol. In the groups receiving ampicillin or doxycycline, marked reductions were found in most of the subjects. No alterations were found in the groups receiving co‐trimoxazole, nalidixic acid or ofloxacin. In 6 subjects no conversion of cholesterol to coprostanol was found up to 5 weeks after the end of the antibiotic intake. We conclude that orally given antibiotics may cause alterations in the intestinal conversion of cholesterol, reflecting changes in the anaerobiC., Gram‐positive component of the gut flora.